within Pharmacolibrary.Drugs.C_CardiovascularSystem.C02D_ArteriolarSmoothMuscleAgentsActingOn.C02DB04_Cadralazine;
model Cadralazine 
   extends Pharmacolibrary.Drugs.ATC.C.C02DB04;

  annotation(Documentation(
    info ="<html><body><p>Cadralazine is a peripheral vasodilator of the hydrazinophthalazine chemical class, previously used as an antihypertensive agent. It acts by relaxing the smooth muscles in the blood vessels, leading to lowered blood pressure. Cadralazine is not in widespread clinical use today and is not approved in most markets.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies with explicit parameter values are available for cadralazine. Values are estimated based on typical pharmacokinetics of structurally related hydrazinophthalazine antihypertensives in adults, assuming oral administration.</p><h4>References</h4><ol><li><p>Lecaillon, JB, et al., &amp; Glorioso, M (1991). Pharmacokinetics of cadralazine in a large group of hypertensive patients chronically treated with cadralazine: advantage over a conventional study in a small group of patients. <i>Therapeutic drug monitoring</i> 13(2) 103–108. DOI:<a href=&quot;https://doi.org/10.1097/00007691-199103000-00003&quot;>10.1097/00007691-199103000-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2053115/&quot;>https://pubmed.ncbi.nlm.nih.gov/2053115</a></p></li><li><p>Marichal, JF, et al., &amp; Ménard, J (1992). Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily. <i>European journal of drug metabolism and pharmacokinetics</i> 17(3) 213–220. DOI:<a href=&quot;https://doi.org/10.1007/BF03190148&quot;>10.1007/BF03190148</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1490491/&quot;>https://pubmed.ncbi.nlm.nih.gov/1490491</a></p></li><li><p>Leonetti, G, et al., &amp; Gradnik, R (1988). Pharmacokinetics of cadralazine in hypertensive patients. <i>European journal of drug metabolism and pharmacokinetics</i> 13(4) 295–300. DOI:<a href=&quot;https://doi.org/10.1007/BF03190093&quot;>10.1007/BF03190093</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3243325/&quot;>https://pubmed.ncbi.nlm.nih.gov/3243325</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Cadralazine;
